Management of CKD Without Proteinuria
For patients with CKD and normal to mildly increased albuminuria (A1), focus on blood pressure control targeting systolic BP <120 mmHg, cardiovascular risk reduction with statins, and consider SGLT2 inhibitors if eGFR is 20-45 ml/min/1.73 m² even without proteinuria. 1, 2
Blood Pressure Management
Target systolic blood pressure <120 mmHg using standardized office measurement when tolerated 2. This applies to all CKD patients regardless of proteinuria status. However, use less intensive BP targets in patients with:
- Frailty
- High fall/fracture risk
- Very limited life expectancy
- Symptomatic postural hypotension 2
Restrict sodium intake to <2 g/day (equivalent to <5 g sodium chloride/day) 2.
RAS Inhibitor Use
RAS inhibitors (ACE inhibitors or ARBs) are NOT routinely recommended for CKD patients without proteinuria (A1 category). The KDIGO 2024 guidelines reserve strong recommendations for RASi only in patients with A2 or A3 albuminuria 1, 2.
However, consider starting RASi in non-proteinuric CKD for specific indications 2:
- Hypertension requiring treatment
- Heart failure with reduced ejection fraction
- Other cardiovascular indications
When RASi are used, administer the highest tolerated approved dose, monitor creatinine and potassium within 2-4 weeks, and continue therapy even when eGFR falls below 30 ml/min/1.73 m² 1.
SGLT2 Inhibitor Therapy
SGLT2 inhibitors represent a paradigm shift for non-proteinuric CKD. The 2024 KDIGO guidelines now suggest SGLT2i for adults with eGFR 20-45 ml/min/1.73 m² and urine ACR <200 mg/g (2B recommendation) 1. This is a weaker recommendation than for proteinuric CKD, but still represents an important treatment option.
Do NOT withhold SGLT2i solely based on absence of proteinuria if:
- eGFR is 20-45 ml/min/1.73 m²
- Patient has heart failure (regardless of albuminuria level) 1
Continue SGLT2i even if eGFR falls below 20 ml/min/1.73 m² once initiated, unless not tolerated or kidney replacement therapy begins 2. Temporarily withhold during prolonged fasting, surgery, or critical illness due to ketosis risk 2.
Cardiovascular Risk Reduction
Statin Therapy
All CKD patients ≥50 years require statin therapy regardless of proteinuria status:
- eGFR <60 ml/min/1.73 m²: statin or statin/ezetimibe combination (1A) 2
- eGFR ≥60 ml/min/1.73 m²: statin alone (1B) 2
For patients 18-49 years, initiate statins if they have coronary disease, diabetes, prior stroke, or 10-year cardiovascular risk >10% 2.
Choose statin regimens that maximize absolute LDL reduction. Consider PCSK-9 inhibitors when indicated 2.
Antiplatelet Therapy
Use low-dose aspirin for secondary prevention in patients with established ischemic cardiovascular disease 2. Consider P2Y12 inhibitors if aspirin intolerant 2.
Monitoring and Surveillance
The absence of proteinuria does not eliminate CKD risk. Research shows that approximately 50% of diabetic patients with renal insufficiency may have minimal or no proteinuria, though they can still have advanced glomerular lesions 3. These patients typically:
- Are older
- Often receive RAS blockers
- Have cardiovascular disease history
- Progress more slowly to end-stage renal disease 3
Monitor regularly:
- eGFR and creatinine
- Albuminuria (annually at minimum)
- Blood pressure
- Potassium and acid-base status
- Cardiovascular risk factors
Additional Management Considerations
Avoid nephrotoxins: NSAIDs, aminoglycosides, and other nephrotoxic agents should be minimized 4.
Manage hyperuricemia: Only treat if symptomatic (gout). Do not use uric acid-lowering therapy for asymptomatic hyperuricemia to delay CKD progression 2.
Dietary modifications: Mediterranean-style diet may reduce cardiovascular risk when combined with lipid therapy 2.
Key Pitfall
The major clinical pitfall is assuming that absence of proteinuria means absence of significant kidney disease or reduced cardiovascular risk. Non-proteinuric CKD still carries substantial morbidity and mortality risk, requiring aggressive cardiovascular risk factor management and consideration of kidney-protective therapies like SGLT2 inhibitors, particularly when eGFR is declining 3, 5.